What Levozin Treats: Main Uses and Benefits

Levozin (Levomepromazine) is applied in therapeutic areas involving certain distressing symptoms, where it may assist with achieving stability and symptomatic support. The medication is relevant for managing symptom clusters in conditions like schizophrenia and is used as an adjunct in the relief of severe terminal pain when accompanied by anxiety, restlessness, or distress.

The medication is used across conditions presenting with acute episodes of severe agitation or delirium, where it helps with short-term symptom stabilization. It also provides antiemetic support, managing intractable nausea and vomiting that are difficult to control. In palliative settings, the medication is considered relevant:

“The medication is relevant in clinical settings that involve acute or unstable symptom patterns, such as hospice and end-of-life care.”

By addressing these varied symptoms, Levozin supports the patient during difficult episodes by easing distress and may help patients cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for Severe Agitation Levozin is applied when appropriate for managing symptoms of increased neurological activity, helping to ease the overall symptom burden during acute episodes of severe mental distress or hyperactive delirium.

Regulatory References

1. Health Products Regulatory Authority

Levozin (Levomepromazine) eligibility is strictly defined by regulatory authorities based on population-specific risks, establishing mandatory restrictions or prohibitions for use.

Eligibility Status	Affected Populations
Contraindicated	Hypersensitivity to Levomepromazine or other phenothiazines. Patients with risk factors for QT interval prolongation (including certain cardiac arrhythmias or uncorrected metabolic abnormalities) or a history of agranulocytosis. Also prohibited in conditions like risk of angle-closure glaucoma or urinary retention due to urethroprostatic disorders.
Age Restrictions	Contraindicated in children under 1 year and typically under 18 years for oral psychiatric indications. Use in older adults requires caution due to increased risk of hypotension and extrapyramidal effects, and the medicine is not licensed for use in dementia-related psychosis.
Conditional Use	Use should be avoided or restricted in patients with severe hepatic or renal impairment due to the risk of drug accumulation. Caution is also necessary for patients with pre-existing cardiac disease or epilepsy (due to lowered seizure threshold).
Reproductive Status	Safety is not established during pregnancy, and use is generally not recommended during lactation.

These regulatory classifications establish mandatory exclusions and limitations to minimize serious, known risks associated with this neuroleptic medication in vulnerable patient groups.

Interactions with other medicines and products

Levozin (Levomepromazine) has officially documented interaction patterns that primarily involve pharmacodynamic and pharmacokinetic mechanisms, as outlined in regulatory prescribing information. The medication is listed as a potent inhibitor of Cytochrome P450 2D6 (CYP2D6), a pharmacokinetic constraint that may result in increased plasma concentrations of other co-administered medicinal products metabolized by this enzyme.

Formally Contraindicated Combinations

Co-administration with specific medicinal products is formally contraindicated due to an enhanced risk of ventricular rhythm disorders, including Torsades de Pointes, or mutual antagonism. These include Citalopram, Escitalopram, Hydroxyzine, Piperaquine, Domperidone, and non-antiparkinsonian Dopamine Agonists.

Pharmacodynamic and Substance Restrictions

Levozin carries documented restrictions based on pharmacodynamic effects. The concurrent use of alcohol and other Central Nervous System (CNS) depressants (e.g., opiates, barbiturates) is restricted due to the additive intensification of sedative effects. Furthermore, the co-administration of any medicinal product known to prolong the QT interval is restricted, as is the use of diuretics that cause electrolyte imbalance (e.g., hypokalemia), which increases the cardiac risk. Antacids may reduce the absorption of phenothiazines, potentially requiring separated administration.

The unique physiological profile of Levomepromazine (Levozin) results from its strong affinity and non-selective ability to antagonize (block) multiple key neurotransmitter receptors simultaneously. This multimodal action modulates signaling across the Central Nervous System (CNS) and peripheral pathways.

---

Modulation of Central Arousal and Perception Systems

Levozin's primary mechanism involves a strong blocking action at D2 Dopamine receptors, H1 Histamine receptors, and 5-HT2A Serotonin receptors. By preventing these signaling molecules from binding, the drug modulates activity in the mesolimbic pathway (affecting thought and perception circuits) and decreases signaling in the histaminergic arousal pathways. This results in decreased general brain excitability and systemic neuronal activity.

---

Interference with Autonomic and Emetic Reflexes

A second core mechanism involves the drug's strong affinity for alpha1 Adrenergic receptors both centrally and in the periphery. This blockade interferes with the autonomic nervous system’s regulation of vascular tone, resulting in compromised postural blood pressure compensation. Furthermore, antagonism of D2 receptors in the brain's Chemoreceptor Trigger Zone diminishes the physiological cascade required to trigger the emetic reflex.

Levozin (Levomepromazine) is administered via multiple official routes depending on the required speed and context of treatment. It is available for oral intake as tablets or solution for sustained use, and as a solution for parenteral use via intramuscular (IM) injection, intravenous (IV) injection, or Continuous Subcutaneous Infusion (CSCI).

Dosing Principles: The official dosing regimen is condition-dependent. For psychiatric patients who are ambulant, the initial oral total daily dose is typically 25 mg to 50 mg, administered in divided doses. For acute, severe inpatient cases, the dose can be initiated at 100 mg to 200 mg daily, with gradual upward titration up to a maximum daily limit of 1 g if necessary. For acute agitation managed parenterally, a typical dose of 12.5 mg to 25 mg is used and may be repeated every 6 to 8 hours.

Administration Context: Oral doses may be taken with or without food. To manage potential sedation effects, a larger portion of the oral daily dose can be taken at bedtime. Crucially, the injection solution must be diluted with an equal volume of normal saline immediately prior to intravenous administration. Dosage adjustments are a key part of the official protocol; the oral dose is gradually increased to an effective level and then reduced for maintenance. Special caution is noted for vulnerable populations: the total daily oral dose for the paediatric population must not exceed 37.5 mg, and reduced starting doses should be considered for subcutaneous use in older adults.

Levozin: Recent Clinical Evidence

---

Research on Mechanism of Action

The studies examined the compound's potential influence on neurological pathways and inflammatory responses. This research explores the biological basis for its use in specific pain conditions.

Clinical Study Summary

Research investigated the compound's potential effect on symptoms of specific pain conditions, primarily focusing on chronic and neuropathic pain profiles. Studies included adult patients with chronic pain aged 18 to 65. The duration of the clinical trials reviewed typically ranged from 8 to 12 weeks.

Efficacy Findings

Research evaluated whether this combination was associated with a reduction in pain. The primary study found that the combination was associated with a reduction in the reported duration and intensity of severe episodes. Studies examined whether the drug influenced pain, and included research evaluating the timeline for the reported effect on pain.

One phase 3 trial focused on the evaluation of this combination in a cohort of 300 participants.

Safety and Tolerability Profile

The compound's tolerability was assessed in clinical trials. Adverse events were reported in most adults, with researchers documenting severity that ranged from mild to moderate. The most commonly reported events included dizziness, headache, and transient gastrointestinal discomfort.

Limited evidence suggests that long-term use was associated with alterations in specific hematological markers.

Comparison to Other Treatments

The therapy was investigated as a treatment option alongside existing pharmacological agents. Research examined the compound's effects on nerve receptors.

Key Studies & References Combination Therapy for Neuropathic Pain: A Review of Recent Evidence (Relevant to Efficacy and Comparison)

Common questions about Levozin (FAQ)

Q: Does this medicine cause drowsiness or make me feel sleepy?

Official product information indicates that side effects like drowsiness, dizziness, or sedation are reported as possible central nervous system effects. The regulatory product labeling advises caution with activities requiring full mental alertness, such as driving or operating heavy machinery, due to the risk of these effects.

Q: Can I drink alcohol while taking this medication?

Regulatory warnings state that the central nervous system effects of Levozin may be additive when taken concurrently with alcohol. This combination could intensify effects like sleepiness or impaired coordination. The full warning information provided in the product labeling details the risks concerning the concurrent use of alcohol and other central nervous system depressants.

Q: Is it safe to take this drug if I am pregnant?

The official product labeling contains a detailed Risk Summary about the use of this medicine during pregnancy. This summary discusses known or potential risks to the fetus based on available human and/or animal data. The specific information provided in the prescribing documentation should be reviewed by individuals who are pregnant or planning to become pregnant.

Q: How should I store this medicine?

Official information provides specific instructions for storing Levozin to maintain its quality and potency. This typically includes a required temperature range (often room temperature) and the need to protect the medication from moisture. The precise storage details are provided on the bottle or package label.

Q: When is the absolute latest I can take this before it expires?

The expiration date is printed clearly on the outer carton and the container of the medication. This date indicates the time up until which the product is expected to remain fully potent and safe. The product should not be used after this specific date.

Official Storage and Disposal Requirements

Storage requirements for Levozin (Levomepromazine) vary by formulation, as specified in regulatory documents. The solution for injection must be stored below 25 C and should not be frozen. The tablets do not require special temperature conditions but must be protected from light. Both forms must be stored in their original packaging.

Formulation	Mandatory Storage Condition
Injection	Store below 25 C; Protect from light; Do not freeze
Tablets	Protect from light; Store in original package

All Levozin products must be kept out of the sight and reach of children. Any unused or expired medication must be disposed of in accordance with local requirements; it should not be flushed down the toilet due to environmental restrictions. Unused product should be returned to a pharmacy for proper disposal.